Primary Immune Thrombocytopenia in Pregnancy: Pathology, Diagnosis, and Management

References

[1] Liu XG, Hou Y, Hou M. How we treat primary immune thrombocytopenia in adults. J Hematol Oncol 2023;16(01):4

[2] Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailler L. Epidemiology of incident immune thrombocytopenia: a nationwide population-based study in France. Blood 2014;124(22):3308-3315

[3] Lee JY, Lee JH, Lee H, et al. Epidemiology and management of primary immune thrombocytopenia: a nationwide populationbased study in Korea. Thromb Res 2017;155:86-91

[4] Obstetrics Subgroup, Chinese Society of Obstetrics and Gynecology, Chinese Medical Association. Expert consensus on diagnosis and treatment of primary immune thrombocytopenia in pregnancy [in Chinese]. Zhonghua Fu Chan Ke Za Zhi 2023;58(03): 170-177

[5] Zhang X, Zhao Y, Li X, et al. Thrombopoietin: a potential diagnostic indicator of immune thrombocytopenia in pregnancy. Oncotarget 2016;7(07):7489-7496

[6] Frölich MA, Datta S, Corn SB. Thrombopoietin in normal pregnancy and preeclampsia. Am J Obstet Gynecol 1998;179(01): 100-104

[7] Dupuis M, Severin S, Noirrit-Esclassan E, Arnal JF, Payrastre B, Valéra MC. Effects of estrogens on platelets and megakaryocytes. Int J Mol Sci 2019;20(12):3111

[8] Bussel JB, Hou M, Cines DB. Management of primary immune thrombocytopenia in pregnancy. N Engl J Med 2023;389(06): 540-548

[9] Reese JA, Peck JD, Deschamps DR, et al. Platelet counts during pregnancy. N Engl J Med 2018;379(01):32-43

[10] Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 2019;3(22):3780-3817

[11] Cines DB, Levine LD. Thrombocytopenia in pregnancy. Blood 2017;130(21):2271-2277

[12] Guillet S, Loustau V, Boutin E, et al. Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study. Blood 2023;141(01):11-21

[13] Lee LO, Bateman BT, Kheterpal S, et al; Multicenter Perioperative Outcomes Group Investigators. Risk of epidural hematoma after neuraxial techniques in thrombocytopenic parturients: a report from the multicenter perioperative outcomes group. Anesthesiology 2017;126(06):1053-1063

[14] Michel M, Ruggeri M, Gonzalez-Lopez TJ, et al. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood 2020;136(26): 3056-3061

[15] Bussel JB, Cooper N, Lawrence T, et al. Romiplostim use in pregnant women with immune thrombocytopenia. Am J Hematol 2023;98(01):31-40

[16] Agarwal N, Mangla A. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review. Ther Adv Hematol 2021;12:20406207211001139

[17] Howaidi J, AlRajhi AM, Howaidi A, AlNajjar FH, Tailor IK. Use of thrombopoietin receptor agonists in pregnancy: a review of the literature. Hematol Oncol Stem Cell Ther 2022;15(01):1-6

[18] Purushothaman J, Puthumana KJ,Kumar A, Innah SJ, Gilvaz S. A case of refractory immune thrombocytopenia in pregnancy managed with elthrombopag. Asian J Transfus Sci 2016;10(02):155-158

RIGHTS & PERMISSIONS

2023 Global Medical Genetics